REVEAL Lite 2 Risk Score: Clinical Guide

Overview

Provides an abridged pulmonary arterial hypertension risk estimate using six non-invasive variables.

Clinical Significance

Scores 1–5 are low risk, 6–7 intermediate risk and 8–14 high risk for 1-year mortality in PAH.

When to Use

• Use as structured clinical decision support when the required data are available and reliable.

How It Is Calculated

• The displayed variables are combined using the published equation, decision rule or weighted point system.

Interpretation

• Scores 1–5 are low risk, 6–7 intermediate risk and 8–14 high risk for 1-year mortality in PAH.

Worked Example

Enter verified patient data in the displayed units; MedicalC applies the published model.

Limitations

• Risk and classification tools can be misapplied outside their validated population.
• Missing, estimated or non-contemporaneous data may materially change the result.

Clinical Pearls

• Document the input values, units, date and clinical setting with the result.
• Use serial scores only when the same instrument and measurement method are used consistently.

Common Mistakes

• Using the tool without confirming entry criteria.
• Using approximate or incorrectly converted laboratory values.
• Treating a prognostic score as a standalone treatment decision.

References

1. Benza RL et al. Chest. 2021;159:337-346. — Primary or supporting reference for the implemented model.